Results 31 to 40 of about 169,996 (318)
Stroke and vascular neurology, 2021 Background In patients with a minor ischaemic stroke or transient ischaemic attack (TIA), separate trials have shown that dual antiplatelet therapy with clopidogrel plus aspirin (clopidogrel–aspirin) or ticagrelor plus aspirin (ticagrelor–aspirin) are ...
Yongjun Wang +13 more
semanticscholar +1 more source
Clopidogrel resistance: The way forward
Indian Heart Journal, 2014 Clopidogrel, a second generation thienopyridine has been the mainstay of ACS (Acute Coronary Syndrome) treatment for more than a decade. Clopidogrel Resistance has been associated with increased mortality in ACS patients with an increase in number of ...
Shuvanan Ray
doaj +1 more source
Clopidogrel and Aspirin in Acute Ischemic Stroke and High‐Risk TIA
New England Journal of Medicine, 2018 BACKGROUND Combination antiplatelet therapy with clopidogrel and aspirin may reduce the rate of recurrent stroke during the first 3 months after a minor ischemic stroke or transient ischemic attack (TIA).
S. Johnston +10 more
semanticscholar +1 more source
Scientific Reports, 2021 Clopidogrel is converted to its active metabolite by cytochrome P450 isoenzymes and irreversibly inhibits platelet activation by antagonizing the adenosine-diphosphate (ADP) receptor.
Yu Ueda +8 more
doaj +1 more source
Journal of the American Medical Association (JAMA), 2020 Importance Current guidelines recommend ticagrelor as the preferred P2Y12 platelet inhibitor for patients with acute coronary syndrome (ACS), primarily based on a single large randomized clinical trial.
S. You +17 more
semanticscholar +1 more source
A study on the impact of CYP2C19 genotype and platelet reactivity assay on patients undergoing PCI
Indian Heart Journal, 2015 Background: A thorough understanding of the patient's genotype and their functional response to a medication is necessary for improving event free survival.
P.C. Rath +9 more
doaj +1 more source
Рациональная фармакотерапия в кардиологии, 2015 Aim. To study prevalence of resistance to acetylsalicylic acid, clopidogrel and dual resistance in percutaneous coronary intervention (PCI), to identify clinical risk factors of resistance development, to study effects of concomitant therapy on ...
V. A. Sulimov, E. V. Moroz
doaj +3 more sources
, 2010 Publisher Summary Clopidogrel contains a center of dissymmetry, and hence is capable of being resolved into its two mirror image compounds. It has been found that only the (S)-enantiomer, which corresponds to the dextrorotatory form, has antithrombotic activity and that the (R)-enantiomer, which corresponds to the levorotatory form, does not exhibit ...
Maria L.A.D. Lestari +3 more
openaire +3 more sources
Effects of clopidogrel on mortality, cardiovascular and bleeding outcomes in patients with chronic kidney disease - data from Taiwan acute coronary syndrome full spectrum registry. [PDF]
PLoS ONE, 2013 BACKGROUND: The efficacy of clopidogrel is inconclusive in the chronic kidney disease (CKD) population with acute coronary syndrome (ACS). Furthermore, CKD patients are prone to bleeding with antiplatelet therapy.
Tsung-Hsien Lin +9 more
doaj +1 more source
Outcome of stroke patients on clopidogrel plus proton-pump inhibitors: a single-center cohort study
Annals of Saudi Medicine, 2019 BACKGROUND: Recent studies suggest a higher risk of adverse cardiovascular outcome and mortality in patients co-prescribed clopidogrel with proton pump inhibitors (PPI). OBJECTIVE: Investigate the impact of concomitant prescription of clopidogrel and PPI
Rahaf A. Alghamdi +4 more
doaj +1 more source